BC Partners and Bpifrance finalise Biogaran deal; Roche returns.

BC Partners and Bpifrance have closed their purchase of Biogaran from Servier, marking a new ownership chapter for one of France’s largest generic-medicine suppliers. The handover follows regulatory clearances and social consultations, with the new owners pledging to preserve the business’s French footprint and operational continuity.

The deal was finalised after Biogaran’s Social and Economic Committee (CSE) issued a favourable opinion on 27 October 2025 and authorities completed the customary EU and French foreign investment reviews. As part of the closing, the acquirers committed to keep the company’s headquarters and core operations in France, protect existing roles and uphold the firm’s subcontracting model.

BC Partners, which brings longstanding European private equity know‑how, will lead the strategic direction while Bpifrance takes a meaningful minority stake and a board seat to reinforce the company’s national anchoring. Both investors have highlighted industrial continuity — from manufacturing and logistics to commercial supply chains — as priorities to ensure patient access and partner stability.

Management changes accompany the ownership shift. Erick Roche will return as Chief Executive Officer, formally taking the reins by the end of March 2026. Roche previously led Biogaran for 15 years and is tasked with consolidating its market position, supporting its workforce of around 270 employees, and accelerating growth across generics and adjacent segments.

For BC Partners, Biogaran represents a strategic foothold in a resilient subsector of healthcare. The firm explicitly flagged expansion into biosimilars and consumer healthcare as potential growth levers — areas where cost containment and therapeutic substitution create both system savings and market opportunities. Market forecasts point to biosimilars expanding at a strong pace over the coming decade, offering material savings for payers and new commercial paths for manufacturers.

From a policy angle, the transaction underscores France’s focus on healthcare sovereignty: public and private capital coordinating to keep critical pharmaceutical manufacturing onshore. Bpifrance framed its involvement as support for long‑term resilience and autonomy in the national health ecosystem, ensuring that strategic supply chains remain anchored domestically.

Looking ahead, the combination of private capital and public support aims to stabilise a key generics supplier while opening runway for product diversification and operational investment. Observers will watch how management balances cost competitiveness with R&D and manufacturing investments, and whether Biogaran follows peers in using M&A or capacity expansion to scale biosimilars production.

In sum, the acquisition secures Biogaran’s independence from its former owner and positions it to play a larger role in France’s generics and biosimilars landscape under the stewardship of BC Partners and Bpifrance.